Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Sjöqvist F[au]:

Clinical pharmacology in Stockholm 50 years-report from the jubilee symposium. Eichelbaum M et al. Eur J Clin Pharmacol. (2018)

Development of clinical pharmacology as a medical speciality in Europe - the roles of WHO, IUPHAR and EACPT. Sjöqvist F et al. Basic Clin Pharmacol Toxicol. (2014)

Clinical Pharmacology in European health care-outcome of a questionnaire study in 31 countries. Orme M et al. Eur J Clin Pharmacol. (2013)

Search results

Items: 1 to 50 of 269

1.

Clinical pharmacology in Stockholm 50 years-report from the jubilee symposium.

Eichelbaum M, Dahl ML, Sjöqvist F.

Eur J Clin Pharmacol. 2018 Jun;74(6):843-851. doi: 10.1007/s00228-018-2432-6. Epub 2018 Feb 27. No abstract available.

2.

Development of clinical pharmacology as a medical speciality in Europe - the roles of WHO, IUPHAR and EACPT.

Sjöqvist F.

Basic Clin Pharmacol Toxicol. 2014 Aug;115(2):172-8. doi: 10.1111/bcpt.12278. Epub 2014 Jun 21. Review.

3.

[The Anti Doping Hot-Line answers questions, educate, network, research...].

Böttiger Y, Gårevik N, Sjöqvist F.

Lakartidningen. 2013 Sep 25-Oct 8;110(39-40):1728-30. Swedish. No abstract available.

PMID:
24245427
4.

Clinical Pharmacology in European health care-outcome of a questionnaire study in 31 countries.

Orme M, Sjöqvist F.

Eur J Clin Pharmacol. 2013 Sep;69(9):1635-9. doi: 10.1007/s00228-013-1519-3. Epub 2013 May 10.

PMID:
23660770
5.

The 'wise list'- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm.

Gustafsson LL, Wettermark B, Godman B, Andersén-Karlsson E, Bergman U, Hasselström J, Hensjö LO, Hjemdahl P, Jägre I, Julander M, Ringertz B, Schmidt D, Sjöberg S, Sjöqvist F, Stiller CO, Törnqvist E, Tryselius R, Vitols S, von Bahr C; Regional Drug Expert Consortium.

Basic Clin Pharmacol Toxicol. 2011 Apr;108(4):224-33. doi: 10.1111/j.1742-7843.2011.00682.x.

6.

Historical perspectives: drug interactions - it all began with cheese.

Sjöqvist F, Böttiger Y.

J Intern Med. 2010 Dec;268(6):512-5. doi: 10.1111/j.1365-2796.2010.02300.x. Epub 2010 Nov 14. No abstract available. Erratum in: J Intern Med. 2011 Mar;269(3):362.

7.

Clinical pharmacology in research, teaching and health care: Considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology.

Birkett D, Brøsen K, Cascorbi I, Gustafsson LL, Maxwell S, Rago L, Rawlins M, Reidenberg M, Sjöqvist F, Smith T, Thuerman P, Walubo A, Orme M, Sjöqvist F.

Basic Clin Pharmacol Toxicol. 2010 Jul;107(1):531-59. doi: 10.1111/j.1742-7843.2010.00602.x. No abstract available.

8.

[Drug clinical trials--the example with antidepressants].

Sjöqvist F.

Lakartidningen. 2008 Jun 3-10;105(23):1734. Swedish. No abstract available.

PMID:
18619018
9.

Use of doping agents, particularly anabolic steroids, in sports and society.

Sjöqvist F, Garle M, Rane A.

Lancet. 2008 May 31;371(9627):1872-82. doi: 10.1016/S0140-6736(08)60801-6. Review.

PMID:
18514731
10.

Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.

Panagiotidis G, Arthur HW, Lindh JD, Dahl ML, Sjöqvist F.

Ther Drug Monit. 2007 Aug;29(4):417-22.

PMID:
17667795
11.
12.

Merck fellowships contribute to the continued growth of clinical pharmacology in Sweden.

Sjöqvist F, Eriksson LO, Andersson KE.

Eur J Clin Pharmacol. 2007 Mar;63(3):229-31. Epub 2007 Jan 18.

PMID:
17235553
13.

Therapeutic monitoring of antiepileptic drugs: a comparison between a Czech and a Swedish University Hospital.

Koristkova B, Bergman U, Grundmann M, Brozmanova H, Sjöqvist F.

Ther Drug Monit. 2006 Oct;28(5):594-8. Erratum in: Ther Drug Monit. 2007 Apr;29(2):264.

PMID:
17038871
14.

The use of TDM data to assess the validity of defined daily doses of antiepileptics: a comparison between a Czech and Swedish University Hospital.

Koristkova B, Sjöqvist F, Grundmann M, Bergman U.

Ther Drug Monit. 2006 Oct;28(5):589-93. Erratum in: Ther Drug Monit. 2007 Apr;29(2):264.

PMID:
17038870
15.

The anti-doping hot-line, a means to capture the abuse of doping agents in the Swedish society and a new service function in clinical pharmacology.

Eklöf AC, Thurelius AM, Garle M, Rane A, Sjöqvist F.

Eur J Clin Pharmacol. 2003 Nov;59(8-9):571-7. Epub 2003 Sep 12.

PMID:
13680032
16.

[Genetic tests give the finishing touch to individual drug dosage].

Sjöqvist F.

Lakartidningen. 2003 Feb 20;100(8):592-3. Swedish. No abstract available.

PMID:
12640970
17.

The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro.

Yasar U, Eliasson E, Forslund-Bergengren C, Tybring G, Gadd M, Sjöqvist F, Dahl ML.

Eur J Clin Pharmacol. 2001 Dec;57(10):729-35.

PMID:
11829203
18.

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.

Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjöqvist F, Eliasson E, Dahl ML.

Clin Pharmacol Ther. 2002 Jan;71(1):89-98.

PMID:
11823761
19.

[Quality assurance of drug prescription in primary health care. A new database software makes the drug therapy surveillance easier].

Engfeldt P, Popa C, Bergensand P, Bernsten C, Lindgren O, Navay I, Sjöqvist F, Svensson E, Stenström P, Tomson Y, Aberg H, Bergman U.

Lakartidningen. 2001 Dec 12;98(50):5767-71. Swedish.

PMID:
11789100
20.

Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers.

Taipalensuu J, Törnblom H, Lindberg G, Einarsson C, Sjöqvist F, Melhus H, Garberg P, Sjöström B, Lundgren B, Artursson P.

J Pharmacol Exp Ther. 2001 Oct;299(1):164-70.

PMID:
11561076
21.

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages.

Kirchheiner J, Brøsen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjöqvist F, Spina E, Brockmöller J.

Acta Psychiatr Scand. 2001 Sep;104(3):173-92. Erratum in: Acta Psychiatr Scand 2001 Dec;104(6):475.

PMID:
11531654
22.
23.

[Pharmacology at the start of a new millennium. Larger assortment and individual drug dosing are coming].

Fredholm BB, Sjöqvist F.

Lakartidningen. 2001 Feb 7;98(6):534-9. Swedish. No abstract available.

PMID:
11475239
24.

Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation.

Alvan G, Bertilsson L, Dahl ML, Ingelman-Sundberg M, Sjöqvist F.

Drug Metab Dispos. 2001 Apr;29(4 Pt 2):580-5. No abstract available.

PMID:
11259356
25.

Mutations of the CYP2C9 gene and the response to warfarin.

Yasar U, Oscarson M, Eliasson E, Sjöqvist F.

Surgery. 2001 Mar;129(3):384. No abstract available.

PMID:
11231472
26.

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.

Scordo MG, Spina E, Romeo P, Dahl ML, Bertilsson L, Johansson I, Sjöqvist F.

Eur J Clin Pharmacol. 2000 Dec;56(9-10):679-83.

PMID:
11214775
27.

Drug safety in relation to efficacy: the view of a clinical pharmacologist.

Sjöqvist F.

Pharmacol Toxicol. 2000;86 Suppl 1:30-2.

PMID:
10905752
28.

Workplace drug testing (WDT) likely to increase in Europe. Report from the First European Symposium on WDT including selected abstracts.

Dalén P, Beck O, Bergman U, Björklöv P, Finer D, Garle M, Sjöqvist F.

Eur J Clin Pharmacol. 2000 Apr;56(1):103-20.

PMID:
10853886
29.

Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics.

Dahl ML, Sjöqvist F.

Ther Drug Monit. 2000 Feb;22(1):114-7. Review.

PMID:
10688272
30.

The past, present and future of clinical pharmacology.

Sjöqvist F.

Eur J Clin Pharmacol. 1999 Oct;55(8):553-7. Review.

PMID:
10541772
31.

Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).

Sandwall P, Lo MW, Jonzon B, Dalén P, Furtek C, Ritter M, Alván G, McCrea J, Sjöqvist F.

Eur J Clin Pharmacol. 1999 Jun;55(4):279-83.

PMID:
10424320
32.

Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöqvist F.

Biochem Biophys Res Commun. 1999 Jan 27;254(3):628-31. Erratum in: Biochem Biophys Res Commun 1999 Apr 29;258(1):227.

PMID:
9920790
33.

Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes.

Yue QY, Zhong ZH, Tybring G, Dalén P, Dahl ML, Bertilsson L, Sjöqvist F.

Clin Pharmacol Ther. 1998 Oct;64(4):384-90.

PMID:
9797795
34.

CYP2D6 and CYP2C19 genotypes in an elderly Swedish population.

Yamada H, Dahl ML, Lannfelt L, Viitanen M, Winblad B, Sjöqvist F.

Eur J Clin Pharmacol. 1998 Aug;54(6):479-81.

PMID:
9776439
35.

No association between familial Alzheimer disease and cytochrome P450 polymorphisms.

Yamada H, Dahl ML, Viitanen M, Winblad B, Sjöqvist F, Lannfelt L.

Alzheimer Dis Assoc Disord. 1998 Sep;12(3):204-7.

PMID:
9772024
36.

Drug use in Estonia in 1994-1995: a follow-up from 1989 and comparison with two Nordic countries.

Kiivet RA, Bergman U, Rootslane L, Rägo L, Sjöqvist F.

Eur J Clin Pharmacol. 1998 Apr;54(2):119-24.

PMID:
9626915
37.

Drug utilization 90%--a simple method for assessing the quality of drug prescribing.

Bergman U, Popa C, Tomson Y, Wettermark B, Einarson TR, Aberg H, Sjöqvist F.

Eur J Clin Pharmacol. 1998 Apr;54(2):113-8.

PMID:
9626914
38.

Ulcer surgery in Estonia, a consequence of drug delay?

Kiivet RA, Bergman U, Sjöstedt S, Sjöqvist F.

Lancet. 1998 Jan 10;351(9096):146. No abstract available.

PMID:
9439528
39.

Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine.

Dalén P, Frengell C, Dahl ML, Sjöqvist F.

Ther Drug Monit. 1997 Oct;19(5):543-4.

PMID:
9357099
40.

Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.

Marandi T, Dahl ML, Rägo L, Kiivet R, Sjöqvist F.

Eur J Clin Pharmacol. 1997;53(3-4):257-60.

PMID:
9476041
41.
42.

Opening address at the 1st Congress of the European Association for Clinical Pharmacology and Therapeutics.

Sjöqvist F.

Therapie. 1996 Jul-Aug;51(4):337-40. No abstract available.

PMID:
8953802
43.

Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.

Marandi T, Dahl ML, Kiivet RA, Rägo L, Sjöqvist F.

Pharmacol Toxicol. 1996 May;78(5):303-7.

PMID:
8737964
44.

The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol.

Jerling M, Dahl ML, Aberg-Wistedt A, Liljenberg B, Landell NE, Bertilsson L, Sjöqvist F.

Clin Pharmacol Ther. 1996 Apr;59(4):423-8.

PMID:
8612387
45.

Antidepressants and drug-metabolizing enzymes--expert group report.

Meyer UA, Amrein R, Balant LP, Bertilsson L, Eichelbaum M, Guentert TW, Henauer S, Jackson P, Laux G, Mikkelsen H, Peck C, Pollock BG, Priest R, Sjöqvist F, Delini-Stula A.

Acta Psychiatr Scand. 1996 Feb;93(2):71-9. Review.

PMID:
8686486
46.

Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.

Kiivet RA, Llerena A, Dahl ML, Rootslane L, Sánchez Vega J, Eklundh T, Sjöqvist F.

Br J Clin Pharmacol. 1995 Nov;40(5):467-76.

47.

Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.

Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F.

J Pharmacol Exp Ther. 1995 Jul;274(1):516-20.

PMID:
7616439
48.

Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia.

Arthur H, Dahl ML, Siwers B, Sjöqvist F.

J Clin Psychopharmacol. 1995 Jun;15(3):211-6.

PMID:
7635999
49.

Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects.

Dahl ML, Yue QY, Roh HK, Johansson I, Säwe J, Sjöqvist F, Bertilsson L.

Pharmacogenetics. 1995 Jun;5(3):159-64.

PMID:
7550367
50.

Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.

Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M.

Mol Pharmacol. 1994 Sep;46(3):452-9.

PMID:
7935325

Supplemental Content

Loading ...
Support Center